Related Experiment Videos

Potential activities of androgen metabolizing enzymes in human prostate

M Krieg1, H Weisser, S Tunn

  • 1Institute of Clinical Chemistry, University Clinic Bergmannsheil, Bochum, Germany.

Insights

5 alpha-reductase is the key enzyme in prostate androgen metabolism, driving DHT levels. Its activity decreases with age in epithelium but not stroma, and finasteride more potently inhibits it in the epithelium.

Area of Science:

  • Andrology
  • Enzymology
  • Prostate Cancer Research

Background:

  • Androgen metabolism is crucial for prostate cellular functions.
  • Dihydrotestosterone (DHT) plays a central role in prostate androgen responsiveness.
  • Understanding enzyme activity and aging's impact is vital for prostate health.

Purpose of the Study:

  • To investigate androgen metabolizing enzyme activities in normal and hyperplastic prostate tissues.
  • To determine the influence of aging on prostate androgen metabolism.
  • To assess the inhibitory effect of finasteride on 5 alpha-reductase.

Main Methods:

  • Quantification of enzyme kinetics (Vmax, Km) using Lineweaver-Burk plots.
  • Calculation of Vmax/Km quotients as an index of potential enzyme activity.
  • Determination of finasteride's 5 alpha-reductase inhibition (IC50) in prostate epithelium and stroma.

Main Results:

  • 5 alpha-reductases exhibited the highest activity among 17 studied enzymes in both normal (NPR) and benign hyperplastic (BPH) prostates.
  • Epithelial 5 alpha-reductase activity and DHT levels significantly decreased with age, unlike in stroma.
  • Finasteride demonstrated stronger inhibition of 5 alpha-reductase in prostate epithelium compared to stroma.

Conclusions:

  • 5 alpha-reductase is the predominant androgen metabolizing enzyme in the prostate, responsible for DHT enrichment.
  • Prostate 5 alpha-reductase activity and DHT levels are significantly affected by aging, particularly in the epithelium.
  • Finasteride preferentially inhibits 5 alpha-reductase in the prostate epithelium, suggesting targeted therapeutic potential.

Related Concept Videos